Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.
Surmodics Inc. (SRDX) drives innovation in medical device coatings and diagnostic solutions through partnerships with global healthcare leaders. This news center delivers verified updates on the company's financial developments, regulatory milestones, and technological breakthroughs shaping patient care.
Find curated press releases detailing SRDX's advancements in vascular intervention systems, diagnostic platform enhancements, and strategic collaborations. Track earnings reports and product launch announcements that highlight the company's transition from coating pioneer to comprehensive medical solution developer.
Our repository includes updates on FDA clearances, clinical study results, and manufacturing expansions critical for assessing SRDX's market position. Discover how the company's surface modification expertise addresses challenges in drug delivery systems and in-vitro diagnostics.
Bookmark this page for ongoing insights into Surmodics' role in medical innovation. Return regularly to stay informed about developments impacting the future of minimally invasive therapies and diagnostic accuracy.
Surmodics, Inc. (NASDAQ: SRDX) announced the successful results of its Pounce™ Thrombectomy System in 20 First-in-Human procedures, achieving 100% technical success. The procedures, presented by Dr. Gary Ansel in London, showed that 19 of 20 patients did not require thrombolytics. The average procedure lasted 79.6 minutes, targeting a range of clot types, predominantly in the superficial femoral and popliteal arteries. This device aims to provide a non-surgical solution for peripheral artery disease, potentially revolutionizing treatment options.
Surmodics (NASDAQ:SRDX) announced that Dr. Gary Ansel will present First-In-Human (FIH) data for the Pounce™ Thrombectomy System on April 26 at the Charing Cross International Symposium in London. This innovative device enables efficient clot removal from peripheral arteries without needing external equipment. Ansel's presentation will review results from the first 20 procedures across six medical centers. The Pounce system aims to improve outcomes for patients with Peripheral Artery Disease (PAD), affecting over 200 million globally.
Surmodics, Inc. (NASDAQ: SRDX) will host a live webcast for its second quarter fiscal 2022 conference call on April 27 at 7:30 a.m. CT. The earnings news release will be issued prior to market open. President Gary Maharaj and CFO Tim Arens will discuss financial results and accomplishments during the call. Interested parties can access the webcast via the company's investor relations website. An audio replay of the call will be available shortly after the event until May 4.
Surmodics specializes in medical device surface modification technologies and aims to enhance disease detection and treatment.
Surmodics, Inc. (Nasdaq: SRDX) will conduct its Annual Meeting of Shareholders on
Surmodics, Inc. (Nasdaq: SRDX) reported a first quarter revenue of $23.0 million, up 3% year-over-year, driven by a 4% increase in Medical Device revenue to $16.9 million. However, the company posted a GAAP EPS loss of $(0.20), worsening from $(0.02) a year ago, while non-GAAP EPS was $(0.13) compared to $0.02 previously. The firm reiterated its 2022 revenue guidance of $97 million to $101 million and projected a GAAP EPS loss of $(2.05) to $(1.55. A potential $30 million milestone from Abbott related to the SurVeil DCB is anticipated for 2022 or 2023.
Surmodics, Inc. (Nasdaq: SRDX) will host a live webcast of its first quarter fiscal 2022 conference call on February 3 at 7:30 a.m. CT. The earnings news release will be issued before the market opens that day. President Gary Maharaj and CFO Tim Arens will recap financial results and accomplishments. An audio replay will be available from 10:30 a.m. CT on February 3 until February 10. Surmodics specializes in surface modification technologies for medical devices and aims to meet unmet clinical needs.
Surmodics, Inc. (NASDAQ: SRDX) will participate in the Sidoti Winter Virtual Investor Conference on January 19, 2022. CEO Gary Maharaj and CFO Tim Arens will present and hold one-on-one meetings with investors. The live audio webcast is scheduled for 10:45 a.m. ET and can be accessed via the company’s investor relations website. This conference emphasizes Surmodics’ commitment to engaging with investors while showcasing its innovations in medical device technologies and in vitro diagnostics.
Surmodics, Inc. (Nasdaq: SRDX) reported a four-year revenue increase of 6% year-over-year for Q4 fiscal 2021, totaling $24.0 million. Medical Device revenue accounted for $17.4 million, while In Vitro Diagnostics revenue rose 23% to $6.6 million. Despite this growth, the company posted a GAAP EPS loss of $(0.02) and a non-GAAP EPS loss of $(0.10). Surmodics aims for fiscal 2022 revenue between $97 million and $101 million and anticipates a potential $30 million milestone payment from a regulatory agreement. They expect a GAAP EPS loss of $(2.05) to $(1.55) in fiscal 2022.
Surmodics, Inc. (Nasdaq: SRDX) will host a live webcast of its fiscal 2021 Q4 conference call on November 10 at 7:30 a.m. CT. The company will release its earnings news prior to market opening that same day. CEO Gary Maharaj and CFO Tim Arens will present the financial results and accomplishments during the call. An audio replay will be available after the call and can be accessed until November 17. Surmodics specializes in surface modification technologies for medical devices and in vitro diagnostics, focusing on innovative solutions for unmet clinical needs.
Surmodics (NASDAQ:SRDX) has announced the successful first clinical uses of the Sublime™ Radial Access .018 RX PTA Dilatation Catheter, expanding its product portfolio. The catheter allows treatment of larger vessels and distal lesions via a radial approach, enhancing complex interventions. It features the longest working length (220 cm) in the market and balloon diameters ranging from 2.0 mm to 6.0 mm. The company is optimistic about the adoption of radial-first strategies due to the better access and lower complication risks associated with this method.
